Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02639910 · ClinicalTrials.gov registry record · Phase 2

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

A Phase 2 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by MorphoSys.

Completed
Registry status
Phase 2
Development phase
24
Enrollment target
17
Study locations

NCT02639910 is a Phase 2 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma that has completed, run by MorphoSys. The registered enrollment target is 24 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (87% lower). The trial reports 17 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02639910, a Phase 2 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, has completed, sponsored by MorphoSys.

COMPLETED
Registry status
Phase 2
Development phase
24 participants
Enrollment target
17
Study locations

Study Summary

This is a two-cohort, multicenter, open-label study of tafasitamab (MOR208) combined with idelalisib or venetoclax in adult patients with R/R CLL or R/R SLL pretreated with a BTK inhibitor (e.g., ibrutinib) as single agent or as part of combination therapy. Patients completing the study treatment are invited to participate in an optional biomarker sub-study.

Conditions Studied

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

  • DRUG Venetoclax
  • DRUG Idelalisib
  • BIOLOGICAL Tafasitamab

Study Locations (17)

Other

  • Clinical Study Site - Graz
  • Clinical Study Site - Salzburg
  • Clinical Study Site - Vienna
  • Clinical Study Site - Dresden
  • Clinical Study Site - Leipzig
  • Clinical Study Site - München
  • Clinical Study Site - Brescia
  • Clinical Study Site - Milan
  • Clinical Study Site - Gdansk
  • Clinical Study Site - Krakow
  • Clinical Study Site - Lublin
  • Clinical Study Site - Opole
  • Clinical Study Site - Bournemouth
  • Clinical Study Site - Leeds

Florida

  • Clinical Study Site - Jacksonville

Minnesota

  • Clinical Study Site - Rochester

Ohio

  • Clinical Study Site - Columbus

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2016-11
Est. Completion 2021-12
Phase Phase 2

Sponsor

MorphoSys

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02639910

The ClinicalTrials.gov registry entry for NCT02639910 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (87% lower). The listed sponsor is MorphoSys, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.

NCT02639910 reports 17 study locations spanning 4 distinct geographic areas - top geographies include Other, Florida, Minnesota.

Frequently Asked Questions

What is clinical trial NCT02639910 about?

NCT02639910 is a clinical study titled "Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi". This is a two-cohort, multicenter, open-label study of tafasitamab (MOR208) combined with idelalisib or venetoclax in adult patients with R/R CLL or R/R SLL pretreated with a BTK inhibitor (e.g., ibrutinib) as single agent or as part of combination therapy. Patients completing the study treatment ar...

What is the current status of trial NCT02639910?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2016-11. Estimated completion is 2021-12.

What conditions does trial NCT02639910 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell.

What interventions are being tested in trial NCT02639910?

The interventions under investigation include: Venetoclax (DRUG), Idelalisib (DRUG), Tafasitamab (BIOLOGICAL).

Who is sponsoring clinical trial NCT02639910?

This trial is sponsored by MorphoSys, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02639910 being conducted?

This trial has 17 study locations across Florida, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Lymphocytic Leukemia

All registered trials for this condition

Small Lymphocytic Lymphoma

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.